Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
Status:
Completed
Trial end date:
2017-12-06
Target enrollment:
Participant gender:
Summary
A Randomized,Two-period, Crossover Study to Determine the Possibility of Drug-drug
Interaction After Co-administration of Metformin and Daclatasvir Where Twenty Eligible Adult
Subjects Will be Randomized to Receive Either Metformin Only and/or Metformin Co-administered
With Daclatasvir to measure primary outcomes including pharmacokinetics parameters as:
Maximum drug concentration in plasma(Cmax), Area under the Plasma concentration Versus Time
Curve from time 0 to 12 hours(AUC0-12), Clearance(CL)
Phase:
Phase 1
Details
Lead Sponsor:
Mohamed Raslan
Collaborators:
Ain Shams University Drug Research Centre, Cairo, Egypt